New cathedral exhibition brings city's medieval citizens to life
'Edinburgh's first Burghers' delves into the lives of medieval citizens who were found in a burial site within the cathedral's grounds.
Commissioned as part of Edinburgh 900 celebrations, new scientific research gives people the chance to learn about the origins, health and even diets of these 'Edinburghers' alongside animated facial areconstructions.
Originally excavated in 1981, these remains have undergone new detailed analysis using advanced methods including ancient DNA sequencing, isotopic analysis, radiocarbon dating, and forensic facial reconstruction. STV News New exhibition delves into the history of people in Edinburgh
City of Edinburgh Council Archaeologist John Lawson said: 'This has been a fascinating project that brings together new archaeological science and the creative arts to tell the story of Edinburgh's first residents in an imaginative and exciting way.
'While we are accustomed to the tales of the famous and powerful, this project shifts the spotlight to the everyday citizens, telling their stories in the very place they once walked, worshipped, and were laid to rest.
'To honour their lives in such a meaningful location has been a rare and powerful opportunity.'
The exhibition invites visitors to explore the Cathedral's medieval past in a new way – bringing faces and stories from Edinburgh's early history to life.
Dr Maria MacLennan from the University of Edinburgh has designed five facial reconstructions of individuals who would have been among the first to call Edinburgh home. STV News Edinburgh College of Art lecturer Dr Maria Maclennan
She told STV News it was a 'really rewarding' project to work on, adding: 'It has been an enormous privilege to contribute to such a fascinating and interdisciplinary project, which adopted a truly interdisciplinary approach requiring collaboration on the part of many.
'Each craniofacial approximation involved the marriage of archaeological evidence together with myriad scientific analyses undertaken by the research team, to help inform final facial appearance: forensic anthropology, radiocarbon dating, isotopic signature, DNA profiling, and forensic-artistic techniques.
'Craniofacial Approximation is a hybrid sci-art practice dedicated to restoring the face of an unknown individual from their skeletal remains. In archaeological contexts, as is seen here in St. Giles' Cathedral, the practice is often an important means of restoring visibility, identity, and humanity to those long lost or forgotten, and/or in promoting education and encouraging public engagement with historical figures of interest from the past.
'For each reconstruction, I produced both a more 'neutral' face (depicting how the individual may present in contemporary day Edinburgh), in addition to a 'historical' face, depicting the individual dressed in clothing/artefacts typical of the time in which they lived.'
'Edinburgh's first Burghers' is free to visit and will be open to the public until November 30 of this year.
Get all the latest news from around the country Follow STV News
Scan the QR code on your mobile device for all the latest news from around the country
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
STV News
2 days ago
- STV News
'Scotland offers rugged adventurous spirit of The Odyssey'
An expert has said Scotland offers the 'adventurous spirit' of The Odyssey as filming for Christopher Nolan's movie adaptation of Homer's epic poem has been taking place in Moray. Stars like Matt Damon, Tom Holland and Zendaya have been spotted in the area filming the upcoming blockbuster. Peter Jolly The film is described by Universal Pictures as a 'mythic action epic' and is being filmed at Findlater Castle overlooking the Moray Firth. As well as A-list celebrities, set pieces including Viking-style ships have been seen in the area. Mid Lothian Council Nicolette Pavlides, a lecturer in Greek Art and Archaeology at the University of Edinburgh, spoke about the accuracy of the pieces, saying the ships made her chuckle. 'The boats were interesting, from looking at the images, they don't look like what Greek ships looked like at the time the story was composed or set,' she told STV News. 'I've heard Nolan doesn't like using CGI much, so he might be using these models that are available rather than that, but the ships at the time of the poems would be very different-looking ships; it made me chuckle.' Ahead of the film's release, Universal Pictures released a picture of Matt Damon, who will play the main protagonist Odysseus, in costume. Universal Pictures Ms Pavlides said the uniform also doesn't accurately represent the period of the story and looks more like a warrior from the classical period. 'The story is supposedly set around 1200 BC, and during that time, warriors looked very different. We know they wore boar tusk helmets from archaeological discoveries,' she said. She added that it's hard to say for definite how the armour should look, but said it will be familiar to the audience. 'I think for this film, the Hoplite armour is how the audience would expect it to look. It's not accurate about what archaeologists would depict, but what the audience would expect, which is probably why the director chose it.' Ms Pavlides said Nolan chose to film scenes in Scotland because of its 'rugged beauty.' 'The story is an epic journey around the Mediterranean, filled with monsters and an unknown, wonderous world outside of ancient Greece and into the wilderness.' Adobe Stock 'I do think that Scotland's rugged coast and striking landscape give you a global perspective, and give the director the chance to create an immersive environment beyond normal Greek landscapes,' she added. 'The dramatic landscape it offers complements the adventurous nature of the story, it's a way to show the adventurous spirit of The Odyssey.' Nolan's adaptation is slated to premiere in cinemas in July 2026. The film boasts an ensemble cast jam-packed with stars including Robert Pattinson, Anne Hathaway, Lupita Nyong'o, Charlize Theron and Jon Bernthal. Get all the latest news from around the country Follow STV News Scan the QR code on your mobile device for all the latest news from around the country
South Wales Guardian
19-07-2025
- South Wales Guardian
RSV jab in pregnancy can ‘significantly' cut baby's infection risk, study finds
A team of researchers co-led by the University of Edinburgh said giving pregnant women the respiratory syncytial virus (RSV) vaccine led to a 72% reduction in babies being hospitalised with the virus. RSV can lead to a severe lung infection called bronchiolitis, which is dangerous in babies and can result in them being admitted to intensive care. It is the main infectious cause of hospitalisation for babies in the UK and globally. The study saw researchers examine 537 babies across England and Scotland who were admitted to hospital with severe respiratory disease in the winter of 2024-25. A total of 391 of the babies tested positive for RSV. The team found mothers of babies who did not have RSV were twice as likely to have received the vaccine before giving birth than the mothers of RSV-positive babies (41% as opposed to 19%). They also found receiving the vaccine more than two weeks before giving birth increased the level of protection, with a 72% reduction in hospital admissions in this group compared with 58% for babies whose mothers were vaccinated at any time prior to delivery. The RSV vaccine was introduced across the UK in the late summer of 2024. The scientists said it works by causing the mother to produce antibodies – proteins which help prevent the virus causing severe infection – which are then passed to the fetus, providing protection from severe RSV for the first six months of their child's life. They recommend women get vaccinated as soon as possible from 28 weeks of pregnancy to provide the best protection, as this allows more time for the mother to generate and pass on protective antibodies to the baby, but the jab can be given up to birth. They also said previous research shows only half of expectant mothers in England and Scotland are currently receiving the RSV vaccine, despite its high success at preventing serious illness. Study lead Dr Thomas Williams, from the University of Edinburgh's Institute for Regeneration and Repair, said: 'With the availability of an effective RSV vaccine shown to significantly reduce the risk of hospitalisation in young infants in the UK, there is an excellent opportunity for pregnant women to get vaccinated and protect themselves and their infants from RSV bronchiolitis this coming winter.' Professor Damian Roland, from the Leicester Hospitals and University and a consultant in paediatric emergency medicine, said: 'Our work highlights the value of vaccination and in keeping with the treatment to prevention principle of the NHS 10 Year plan, we would ask all health care systems to consider how they will optimise the rollout of RSV vaccination for mothers.' The research team was led by the universities of Edinburgh and Leicester, and was funded by the Innovative Medicines Initiative, Respiratory Syncytial Virus Consortium in Europe, the Wellcome Trust, and National Institute for Health and Care Research at Imperial College London. The study is published in the journal The Lancet Child and Adolescent Health.
North Wales Chronicle
19-07-2025
- North Wales Chronicle
RSV jab in pregnancy can ‘significantly' cut baby's infection risk, study finds
A team of researchers co-led by the University of Edinburgh said giving pregnant women the respiratory syncytial virus (RSV) vaccine led to a 72% reduction in babies being hospitalised with the virus. RSV can lead to a severe lung infection called bronchiolitis, which is dangerous in babies and can result in them being admitted to intensive care. It is the main infectious cause of hospitalisation for babies in the UK and globally. The study saw researchers examine 537 babies across England and Scotland who were admitted to hospital with severe respiratory disease in the winter of 2024-25. A total of 391 of the babies tested positive for RSV. The team found mothers of babies who did not have RSV were twice as likely to have received the vaccine before giving birth than the mothers of RSV-positive babies (41% as opposed to 19%). They also found receiving the vaccine more than two weeks before giving birth increased the level of protection, with a 72% reduction in hospital admissions in this group compared with 58% for babies whose mothers were vaccinated at any time prior to delivery. The RSV vaccine was introduced across the UK in the late summer of 2024. The scientists said it works by causing the mother to produce antibodies – proteins which help prevent the virus causing severe infection – which are then passed to the fetus, providing protection from severe RSV for the first six months of their child's life. They recommend women get vaccinated as soon as possible from 28 weeks of pregnancy to provide the best protection, as this allows more time for the mother to generate and pass on protective antibodies to the baby, but the jab can be given up to birth. They also said previous research shows only half of expectant mothers in England and Scotland are currently receiving the RSV vaccine, despite its high success at preventing serious illness. Study lead Dr Thomas Williams, from the University of Edinburgh's Institute for Regeneration and Repair, said: 'With the availability of an effective RSV vaccine shown to significantly reduce the risk of hospitalisation in young infants in the UK, there is an excellent opportunity for pregnant women to get vaccinated and protect themselves and their infants from RSV bronchiolitis this coming winter.' Professor Damian Roland, from the Leicester Hospitals and University and a consultant in paediatric emergency medicine, said: 'Our work highlights the value of vaccination and in keeping with the treatment to prevention principle of the NHS 10 Year plan, we would ask all health care systems to consider how they will optimise the rollout of RSV vaccination for mothers.' The research team was led by the universities of Edinburgh and Leicester, and was funded by the Innovative Medicines Initiative, Respiratory Syncytial Virus Consortium in Europe, the Wellcome Trust, and National Institute for Health and Care Research at Imperial College London. The study is published in the journal The Lancet Child and Adolescent Health.
